Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Acquisitions (Details Textual)

v3.5.0.2
Note 2 - Acquisitions (Details Textual)
$ in Thousands
 3 Months Ended
Aug. 01, 2016
USD ($)
Jul. 01, 2016
USD ($)
Mar. 14, 2016
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Zephyrus [Member] | In Process Research and Development, Not Amortizable [Member]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 7,400    
Zephyrus [Member] | Developed Technology Rights, Converted from In Process Research and Development [Member]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 8,300  
Zephyrus [Member] | Instruments Sales Contingency [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     $ 3,500    
Business Combination, Contingent Consideration, Liability, Number of Instruments Sold     10    
Business Combination, Contingent Consideration, Liability, Anniversary of Closing Date     3 years    
Business Combination, Contingent Consideration, Liability, Cumulative Sales     $ 3,000    
Zephyrus [Member]          
Payments to Acquire Businesses, Gross     8,000    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     7,000    
Business Combination, Contingent Consideration, Liability     $ 6,900    
Space [Member]          
Payments to Acquire Businesses, Gross   $ 9,000      
Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Equal or Exceed $30 Milliom [Member]          
Business Combination, Contingent Consideration, Liability $ 25,000        
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue 30,000        
Advanced Cell Diagnostics (ACD) [Member] | The 2017 Revenues Equal or Exceed $45 Million [Member]          
Business Combination, Contingent Consideration, Liability 50,000        
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue 45,000        
Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Hurdle Not Met and 2017 Revenue Hurdle Met [Member]          
Business Combination, Contingent Consideration, Liability 25,000        
Advanced Cell Diagnostics (ACD) [Member] | Trigger a Reduced Earn-Out Payment [Member] | Minimum [Member]          
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue 40,000        
Advanced Cell Diagnostics (ACD) [Member] | Trigger a Reduced Earn-Out Payment [Member] | Maximum [Member]          
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue 45,000        
Advanced Cell Diagnostics (ACD) [Member] | Selling, General and Administrative Expenses [Member]          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability       1,900  
Advanced Cell Diagnostics (ACD) [Member]          
Payments to Acquire Businesses, Gross 250,000        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 75,000        
Business Combination, Contingent Consideration, Liability $ 38,200     $ 40,100  
Developed Technology Rights [Member]          
Finite-Lived Intangible Asset, Useful Life       15 years  
Trade Names [Member]          
Finite-Lived Intangible Asset, Useful Life       7 years 182 days  
Customer Relationships [Member]          
Finite-Lived Intangible Asset, Useful Life       10 years  
Noncompete Agreements [Member]          
Finite-Lived Intangible Asset, Useful Life       2 years  
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability       $ 1,900